PatientsHCPs
This site is for US Health Care Professionals only

LEQVIO is for LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1

.

Not an actual patient.

*An event is defined as acute coronary syndrome (unstable angina, STEMI, or NSTEMI).3

.

†Greater LDL-C reduction was maintained during each 6-month dosing interval vs placebo as a complement to a maximally tolerated statin.1

.

Actor portrayal.

After a CV event, reaching and remaining at LDL-C target is critical4

SEE WHY

CAD, coronary artery disease; CV, cardiovascular; LDL-C, low-density lipoprotein cholesterol; NSTEMI, non-ST-elevation myocardial infarction; STEMI, ST-elevation myocardial infarction.

.
References: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp. 2. Wright RS, Raal FJ, Koenig W, et al. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. Oral presentation at: European Society of Cardiology; August 25-28, 2023; Amsterdam, Netherlands. 3. Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. StatPearls. Treasure Island (FL): StatPearls Publishing; July 10, 2023. 4. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018 Sep 4;72(10):1141-1156. doi: 10.1016/j.jacc.2018.06.046. PMID: 30165986.